Drug Trial Radar · NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,960
Planned (sponsor's estimate)
Start
Oct 18, 2023
Primary completion
Jan 2032
Study completion Jul 2034
Sponsor
- Lead sponsor
- NRG OncologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- May 30, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Conditions
- Breast Cancer
Interventions
Ovarian Function Suppression + Aromatase InhibitorDrug
Aromatase inhibitor co-administered with a GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Adjuvant Chemotherapy + Ovarian Function SuppressionDrug
Adjuvant chemotherapy of investigator's choice followed by an aromatase inhibitor (AI) co-administered with an GnRH agonist for 5 years. The choice of AI is per investigator discretion. The choice of GnRH agonist and dosing schedule is per investigator's discretion. Options commonly include goserelin, leuprolide, or triptorelin given monthly or every-three-months. The dose and schedule of AI should be consistent with the drug package insert. Endocrine treatment beyond 5 years is at the investigator's discretion. Bilateral oophorectomy may substitute for ovarian suppression if desired.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Invasive breast cancer-free survival (IBCFS)Time frame: Time from randomization for duration of trial, 11 years
Locations
1,276 sites in 9 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Recruiting
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Recruiting
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Recruiting
Alaska Women's Cancer Care
Anchorage, Alaska · Recruiting
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Recruiting
Providence Alaska Medical Center
Anchorage, Alaska · Recruiting
Fairbanks Memorial Hospital
Fairbanks, Alaska · Recruiting
Kingman Regional Medical Center
Kingman, Arizona · Recruiting
Cancer Center at Saint Joseph's
Phoenix, Arizona · Recruiting
Mayo Clinic Hospital in Arizona
Phoenix, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Recruiting
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
Baptist Health Medical Center - Little Rock
Little Rock, Arkansas · Recruiting
CARTI Cancer Center
Little Rock, Arkansas · Recruiting
University of Arkansas for Medical Sciences
Little Rock, Arkansas · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Kaiser Permanente-Deer Valley Medical Center
Antioch, California · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Recruiting
PCR Oncology
Arroyo Grande, California · Recruiting
Sutter Auburn Faith Hospital
Auburn, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California · Recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California · Recruiting
Tower Cancer Research Foundation
Beverly Hills, California · Recruiting
Keck Medicine of USC Buena Park
Buena Park, California · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Recruiting
Mills-Peninsula Medical Center
Burlingame, California · Recruiting
Marshall Cancer Center
Cameron Park, California · Recruiting
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Recruiting
Mercy San Juan Medical Center
Carmichael, California · Recruiting
Eden Hospital Medical Center
Castro Valley, California · Recruiting
Enloe Medical Center
Chico, California · Recruiting
Enloe Cancer Center
Chico, California · Recruiting
Sutter Davis Hospital
Davis, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Active not recruiting
Showing 40 of 1,276 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.